日本質量分析学会 第66回質量分析総合討論会

Program

Oral Sessions

Day 4, May 18(Fri.) 09:00-09:15 Room B (Seiun 1)

Comprehensive phosphoproteomics from biopsy specimens

(1NIBIOHN, 2Natl. Cancer Ctr. Hosp.)
oYuichi Abe1, Hirokazu Syoji2, Hirano Hirano2, Jun Adachi1, Narikazu Boku2, Takeshi Tomonaga1

In recent years, drugs targeting kinases have been widely used for anti-cancer therapy. However, severe side effects or resistance are occasionally reported. Therefore, it is critical to find molecular markers which reflect drug sensitivity for construction of effective treatment strategy.
The development of omics database from surgical specimens has been proceeded. As a result, the integrative analysis of different omics layers revealed relationship between genomic abnormality and modulated phosphosignalings in breast cancer1) and ovarian cancer2).
Such comprehensive analyzes using surgical specimens has made a great contribution to cancer biology, but interpretation of the result, especially phosphoproteomic data, needs to be done carefully. It is reported that the ischemia due to ligation during surgery greatly affects phosphoproteomics in cancer tissues3). Therefore, analysis of biopsy specimens reflecting more physiological state in cancer has been desired. However, global phosphoproteomics has been difficult due to difficulties such as small size of specimens (<2 mm) and contaminants in tissues.
In this study, we examined global phosphoproteomics from biopsy specimens. We succeeded in identification of more than 10,000 class 1 phosphosites by improving our protocol more suitable for small samples. This result would greatly contribute to clinical diagnosis based on molecular profiling in biopsy specimens.